Characterization of Two TNF-Related Subtypes Predicting Infliximab Therapy Responses in Crohn's Disease.

ABSTRACT:

Background

Anti-tumor necrosis factor (TNF) therapy is widely used to treat Crohn's disease (CD). Unfortunately, 10%-40% of patients have primary non-response to anti-TNF therapy. TNF family genes play crucial roles in inflammation and immune regulation; however, the effects of TNF family genes on CD remain unclear.

Methods

CD expression profiles were downloaded from the Gene Expression Omnibus database. Unsupervised clustering was then used to identify the gene subtypes in CD based on the expressions of TNF family genes. The features of the gene subtypes were characterized using functional enrichment and immune infiltration analyses, and biomarkers of the gene subtypes were identified.

Results

Patients with CD were divided on the basis of unsupervised clustering into

SUBMITTER: Ye C 

PROVIDER: S-EPMC9072632 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature